Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 244 participants.
Also called NCT05184088
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose diagnostic
- Phase
- Phase 3
- Enrolled
- 244 participants
- Sponsor
- Lantheus Germany GmbH
- Registry
-
NCT05184088
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Germany, Spain, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT05184088. Allocation not applicable; no masking; primary purpose diagnostic. Start 2023-01-13 (actual); primary completion 2026-04-21 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis
- Acronym
- CArdiag
- Condition
- Cardiac Amyloidosis
- Condition
- AL Amyloidosis
- Condition
- ATTR Amyloidosis
- Intervention (Drug)
- [18F]florbetaben
- Lead sponsor
- Lantheus Germany GmbH
- Collaborator
- pharmtrace klinische Entwicklung GmbH
Record details
- Record id
cardio:ct-nct05184088- Content hash
ee456643bc9517a64ee8d238fa988e1ebae93384b459fc09205f533372a0b456